SCHEMBL6324176

SCHEMBL6324176

FC(F)(F)Oc1ccc(-c2cccc3[nH]ccc23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 3/20 0.56
BCR P11274 2/20 0.56
PIK3CD O00329 3/20 0.54
GOT1 P17174 1/20 0.46
PIK3CB P42338 2/20 0.45
PIK3CG P48736 1/20 0.44
ASH1L Q9NR48 1/20 0.43
ATM Q13315 1/20 0.41
KIF11 P52732 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
TTBK1 Q5TCY1 1/20 0.40
TTBK2 Q6IQ55 1/20 0.40
STING1 Q86WV6 1/20 0.40
JAK2 O60674 1/20 0.39
PRKD3 O94806 1/20 0.39
MARK3 P27448 1/20 0.39
PRKCI P41743 1/20 0.39
PRKCD Q05655 1/20 0.39
CAMK2B Q13554 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6326839 0.85 ASH1L (0.51) ABL1BCRPIK3CDGOT1PIK3CB
SCHEMBL7090984 0.80 PIK3CD (0.63) PIK3CDGOT1PIK3CBPIK3CGASH1L
SCHEMBL6322049 0.80 PIK3CD (0.58) ABL1BCRPIK3CDGOT1PIK3CB
SCHEMBL31413326 0.80 PIK3CD (0.58) ABL1BCRPIK3CDGOT1PIK3CB
SCHEMBL28109256 0.79 BRD4 (0.49) ABL1BCRPIK3CDTTBK1TTBK2
SCHEMBL7088143 0.78 PIK3CD (0.57) PIK3CDGOT1PIK3CBPIK3CGASH1L
SCHEMBL10945814 0.78 PIK3CD (0.75) PIK3CDPIK3CBPIK3CGASH1LCSNK2B
SCHEMBL18002679 0.78 ABL1 (0.45) ABL1BCRPIK3CDGOT1PIK3CB
SCHEMBL6322152 0.77 PIK3CD (0.64) ABL1PIK3CDPIK3CBPIK3CGASH1L
SCHEMBL27725234 0.75 PIK3CD (0.66) PIK3CDPIK3CBPIK3CGASH1LCSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
US-20030203959-A1 Novel modulators of potassium channels 4SC AG (DE) 2003-10-30 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ABL1 20/4885BCR 1129/4885PIK3CD 365/4885
US-20030203959-A1 Novel modulators of potassium channels HCN3, KCNN3, KCNN1 ABL1 3070/4885BCR 2549/4885PIK3CD 3331/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ABL1 20/4885BCR 1129/4885PIK3CD 365/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.